News

SAGAsafe® technology utilized in new study of ESR1 mutations in breast cancer

  LUND, Sweden — /April 22, 2021/ — ESR1 mutations are found in primary breast cancers prior to therapy initiation and are associated to worse relapse-free and overall survival. These results were reported today by a group of researchers from Lund University and Skåne University Hospital in a new studied…

Now recruiting: Molecular Diagnostics Scientist NGS

Molecular Diagnostics Scientist, NGS   Do you want to help usher in advanced cancer diagnostics and monitoring to improve patient quality of life and survival?   SAGA Diagnostics AB is seeking a talented and highly motivated NGS scientist with strong interest in advancing our mission to revolutionize cancer diagnostics through…

SAGA Diagnostics co-financed in the EU Commission’s TIGER grant of EUR 6.9 million led by eTheRNA Immunotherapies

  LUND, Sweden — /March 23, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces the participation in the EU H2020 funded consortium grant TIGER together with seven other partners and led by…

SAGA presenting at the EACR-OECI virtual conference: Molecular Pathology Approach to Cancer on March 23-24

Molecular pathology is revolutionizing clinical practice in oncology and pathology paving the way for precision medicine, and has evolved into a growing research field.     SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, is proud…

SAGA awarded €200,000 grant from Sweden’s innovation agency Vinnova

  LUND, Sweden — /March 16, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has been awarded a grant of 2.0 MSEK (~ €200,000) from the Swedish Governmental Agency for Innovation Systems (Vinnova) under the…

SAGA Diagnostics enters into Agreement with Alligator Bioscience in the phase 1b/2 OPTIMIZE-1 trial

LUND, Sweden — /February 25, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into a service agreement with Alligator Bioscience, a Swedish clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs.   SAGA…

SAGA enters collaboration with Institut Curie in the MONDRIAN trial

LUND, Sweden — /February 2, 2021/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, announced today its collaboration with the French comprehensive cancer center Institut Curie in the MONDRIAN breast cancer clinical trial.   The…

SAGA Diagnostics announces CE-marking of SAGAsafe® EGFR T790M assay and hiring of two Sales Managers

  LUND, Sweden — /October 20, 2020/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announced the CE IVD-marking of its SAGAsafe® EGFR T790M assay*.   The assay is a digital PCR test run on…

SAGA Diagnostics and SensID collaborate on ultra-low allelic frequency control reagents for cancer mutations

ROSTOCK and LUND — /July 15, 2020/ — SensID GmbH, headquartered in Rostock, Germany, is a specialist for development and production of reference control materials for clinical genomics. SAGA Diagnostics AB, headquartered in Lund, Sweden, is a cancer genomics company focused on precision oncology and ultrasensitive liquid biopsy monitoring of cancer patients.  Today…

SAGA enters into research collaboration with University College London

LUND, Sweden — /June 17, 2020/ — SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announced a research collaboration with University College London (UCL) Cancer Institute.   In the course of this collaboration, SAGA will design…